European Medicines Agency validates Bristol Myers Squibb’s application for zeposia (ozanimod) for the treatment of ulcerative colitis
Marketing Authorization Application is supported by positive results from the pivotal Phase 3 True North study evaluating oral Zeposia (ozanimod) in adults with moderately to severely active ulcerative colitis If approved, Zeposia would be the first oral sphingosine-1-phosphate (S1P) receptor modulator for